NCT03149770View on ClinicalTrials.gov

Naloxone, Hypoglycemia and Exercise

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

May 1, 2022

Study Completion Date

April 1, 2023

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Naloxone then placebo

naloxone intranasal 4mg, then placebo

DRUG

Placebo then Naloxone

placebo then naloxone intranasal 4mg

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT03149770 - Naloxone, Hypoglycemia and Exercise | Biotech Hunter | Biotech Hunter